<DOC>
	<DOCNO>NCT00586898</DOCNO>
	<brief_summary>Objective : To determine response rapid hormonal cycling patient non-castrate prostate cancer .</brief_summary>
	<brief_title>Rapid Hormonal Cycling Treatment Patients With Prostate Cancer : The Men 's Cycle</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Patients reside follow clinical state wit ! consider : A . Rising PSA : Patients history localize disease undergone definitive radiation surgery . These patient must demonstrate progression disease biochemically outline . Patients group may radiographically evident disease . B. Noncastrate metastatic : Patients must present radiographic evidence metastatic disease time diagnosis treatment localized disease . These patient must show newly detect disease progress disease bone soft tissue . Biochemical progression define : minimum . determination : 3 Interval : &gt; 2 week Minimal Baseline PSA value ( ng/ml ) : 2 Minimal % increase range value : 50 % Diagnosis prostate adenocarcinoma histologically confirm MSKCC . Patient must level serum testosterone low limit normal . Karnofskcy performance status ( KPS ) &gt; _70 % . Patients must adequate organ function define follow laboratory criterion : WBC &gt; _3500/mm3 , platelet count &gt; _100,000/mm3 . Bilirubin &lt; 2.0 mg/dl SGOT &lt; 3.0 X upper limit normal . Creatinine &lt; _1.6 mg/dl creatinine clearance &gt; _60 cc/min . Prior hormonal therapy allow : 1 . Neoadjuvant treatment prior radiation therapy radical prostatectomy , provide total duration exposure exceed 10 month . 2 . One cycle intermittent therapy maximum exposure 10 month . Patients must least 18 year age . Patients must sign informed consent document state understand investigational nature propose treatment Clinically significant cardiac disease ( New York Heart Association Class III/IV ) , severe debilitate puhnonary disease . Uncontrolled serious active infection . Anticipated survival le 3 month . Active CNS epiduraltumor Inability unwillingness comply treatment protocol , followup , research test .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hormones</keyword>
	<keyword>01-085</keyword>
	<keyword>ANTIFUNGAL ANTIBIOTICS</keyword>
	<keyword>ESTROGENS</keyword>
	<keyword>LUPRON</keyword>
	<keyword>TESTOSTERONE</keyword>
	<keyword>ZOLADEX</keyword>
</DOC>